MAI Capital Management Has $10.02 Million Stock Holdings in Pfizer Inc. $PFE

MAI Capital Management grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.7% in the third quarter, Holdings Channel reports. The institutional investor owned 393,049 shares of the biopharmaceutical company’s stock after acquiring an additional 28,163 shares during the period. MAI Capital Management’s holdings in Pfizer were worth $10,015,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. RWA Wealth Partners LLC lifted its position in Pfizer by 2.3% in the 3rd quarter. RWA Wealth Partners LLC now owns 237,439 shares of the biopharmaceutical company’s stock valued at $6,050,000 after acquiring an additional 5,231 shares in the last quarter. Cary Street Partners Financial LLC raised its stake in shares of Pfizer by 6.8% in the third quarter. Cary Street Partners Financial LLC now owns 261,861 shares of the biopharmaceutical company’s stock worth $6,672,000 after purchasing an additional 16,705 shares during the last quarter. Bradley Foster & Sargent Inc. CT lifted its holdings in shares of Pfizer by 12.5% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 587,805 shares of the biopharmaceutical company’s stock valued at $14,977,000 after purchasing an additional 65,206 shares in the last quarter. JFS Wealth Advisors LLC boosted its position in shares of Pfizer by 10.4% during the third quarter. JFS Wealth Advisors LLC now owns 47,690 shares of the biopharmaceutical company’s stock valued at $1,215,000 after buying an additional 4,485 shares during the last quarter. Finally, Waddell & Associates LLC grew its holdings in Pfizer by 7.3% during the third quarter. Waddell & Associates LLC now owns 24,278 shares of the biopharmaceutical company’s stock worth $619,000 after buying an additional 1,660 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.1%

Pfizer stock opened at $27.11 on Thursday. The firm has a 50 day moving average price of $26.04 and a 200-day moving average price of $25.37. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The company has a market capitalization of $154.11 billion, a P/E ratio of 19.93 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. Pfizer’s revenue was down 1.2% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Barclays assumed coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. Bank of America cut their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Morgan Stanley reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Royal Bank Of Canada started coverage on shares of Pfizer in a research report on Tuesday. They set an “underperform” rating and a $25.00 target price on the stock. Finally, HSBC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Pfizer in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $27.70.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants full approval to the BRAFTOVI (encorafenib) combination regimen for first‑line metastatic colorectal cancer with BRAF V600E mutation — a label expansion based on the Phase 3 BREAKWATER trial that de‑risks and commercializes a late‑stage oncology asset, supporting potential incremental sales and long‑term oncology upside. U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
• Positive Sentiment: Pfizer inks a China commercialization/licensing deal for Sciwind’s ecnoglutide (a next‑gen biased GLP‑1) with up to ~$495M in potential payments — accelerates Pfizer’s obesity/diabetes footprint in a large market and signals management’s push into metabolic medicines beyond acquisitions. Pfizer in diabetes drug deal with Sciwind Biosciences
• Positive Sentiment: Pipeline momentum: coverage notes highlight BREAKWATER results plus expanded obesity programs (Metsera acquisition and >20 weight‑management studies) — suggests diversification of future growth drivers beyond legacy products. Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results
• Positive Sentiment: Dividend support: coverage reiterates Pfizer’s high dividend yield (attractive income for some investors) and management’s commitment to the payout, which can cushion the stock in choppy markets. This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
• Neutral Sentiment: Pneumococcal vaccine Phase 1 update in China — an early‑stage readout that is informational for the pipeline but unlikely to move top‑line revenue in the near term. Pfizer’s Pneumococcal Vaccine Study in China: What the Latest Trial Update Means for PFE Investors
• Neutral Sentiment: Valuation and performance write‑ups debate whether PFE is offering value after mixed multi‑year returns — useful context for long‑term investors but not an immediate catalyst. Is Pfizer (PFE) Offering Value After Mixed Multi Year Share Price Performance
• Negative Sentiment: Pfizer terminated a Phase 1b ulcerative colitis study — a setback for that early‑stage program and a reminder of R&D risk; impact on revenue is limited but it trims future optionality in immunology. Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study: What Investors Should Watch
• Negative Sentiment: Analyst caution: commentary that Pfizer has underperformed the healthcare sector over the past year could pressure sentiment and limit upside until clearer organic growth or margin inflection is visible. Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.